Ultragenyx Pharmaceutical (RARE)
(Delayed Data from NSDQ)
$44.24 USD
+0.39 (0.89%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $44.23 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
- YR Estimate
- 12/31/2023
- 12/31/2022
- 12/31/2021
- 12/31/2020
- 12/31/2019
- Revenue - Line of Business (LOBR)
- Revenues: Collaboration and license
- 71.18
- 222.71
- 256.44
- 219.32
- 83.49
- Revenue - Line of Business (LOBR)
- Revenues: Product sales
- 180.41
- 118.93
- 77.02
- 38.72
- 20.22
- Revenue - Line of Business (LOBR)
- Revenues: Non-cash collaboration royalty revenue
- 182.65
- 21.69
- 17.95
- 13.00
- --
- Revenue - Line of Business (LOBR)
- Revenues: Product sales: Crysvita
- 328.05
- 42.68
- 21.42
- 10.35
- 4.29
- Revenue - Line of Business (LOBR)
- Revenues: Product sales: Dojolvi
- 70.63
- 55.61
- 39.56
- 13.03
- 3.30
- Revenue - Line of Business (LOBR)
- Revenues: Collaboration and license revenue: Daiichi Sankyo
- 1.48
- 7.69
- 85.00
- 89.22
- --
- Revenue - Line of Business (LOBR)
- Revenues: Product sales: Mepsevii
- 30.44
- 20.64
- 16.04
- 15.34
- 12.63
- Revenue - Line of Business (LOBR)
- Revenues: Product sales: Evkeeza
- 3.64
- --
- --
- --
- --